Ruling It. Yesterday afternoon, the Centers for Medicare & Medicaid Services released the MA/Part D final rule. Personally, most of it was not up my alley but I did read over the changes to the changes to an approved formulary sections. In December 2022, CMS proposed allowing immediate substitution of interchangeable biosimilars or branded biologics…
This morning I attended the Innovation and Value Initiative’s (IVI’s) event on “Ensuring Equity in Implementation of IRA Drug Price Negotiations.” As the discussions went on, I began to believe that ensuring equity in the Inflation Reduction Act (IRA) negotiation process was too herculean. To ensure equity would require… So maybe the title of the…